There are currently no available treatment options for more than 90% of the approximately 7,000 rare diseases identified to date. However, if these conditions result from correctable cellular or genetic defects, cell and gene therapies (CGTs) can significantly improve patients’ quality of life and often represent their only hope for betterment of their condition. The catch is that CGTs come at a substantial cost to both payers and patients.
This article was originally published on MedicalXpress.com
